In this report, we describe the intracellular localization of multimerin in platelets and its biosynthesis by Dami cells, a megakaryocytic cell line. Immunoelectron microscopy was used to examine frozen thin sections of resting and activated platelets. 
Introduction
Multimerin is an extremely large, soluble platelet glycoprotein that is expressed on the surface of activated platelets ( 1, 2) . This protein exists as variably sized multimers that range from < 450 kD to many million daltons ( 1, 2) . Multimerin and von Willebrand factor share a similar complex multimeric composition and our previous studies demonstrated that multimerin and von Willebrand factor are the two largest proteins in platelets (2) . The individual multimers of platelet multimerin are comprised of p-155 and p-170 subunits, linked by disulfide bonds (2) . During platelet activation, multimerin moves from the platelet interior and becomes expressed on the platelet sur-face ( 1 ). The largest multimers ofthis protein remain bound to the platelet surface after activation and the smaller multimers are released (2) .
The intent of the current study was to investigate the location and origin of platelet multimerin. Soluble proteins contained within platelets can originate from two sources: endogenous biosynthesis by megakaryocytes or endocytosis from plasma (3) . In general, proteins synthesized by the megakaryocyte are present at a higher concentration in platelets than in plasma, whereas plasma-derived platelet proteins are present at a greater concentration in plasma than in platelets. Fibrinogen is the only known exception (3). Because we failed to detect multimerin in plasma, we postulated that this protein might be synthesized by megakaryocytes and stored within platelet granules for release upon activation. In this report, we describe the intracellular location of multimerin in platelets. Additionally, we demonstrate the presence of multimerin in normal megakaryocytes and its biosynthesis by Dami cells (4) , a malignant megakaryocytic cell line.
Methods
Antibodies. Monoclonal antibody JS-1 and polyclonal rabbit antibodies against multimerin were used for immunoprecipitation and immunohistochemistry (1) . Immunocytochemistry studies were performed using polyclonal antimultimerin and both monoclonal and polyclonal antibodies to von Willebrand factor (Dako Corp., Carpinteria, CA). These polyclonal antisera to multimerin and von Willebrand factor are non-cross-reactive and recognize reduced platelet proteins of 155 and 220 kD, respectively ( 1, 2) . Additionally, using immunoblot studies, the polyclonal anti-von Willebrand factor does not recognize purified multimerin (1) and polyclonal antibodies to multimerin do not react with purified von Willebrand factor.
Platelet preparation. Washed platelets ( 1 X 108/ml) were activated, without agitation, using bovine thrombin (1 U/ml; Sigma Immunochemicals, St. Louis, MO). After 10 min, recombinant hirudin (Sigma), 4 U/ml, was added. Activated platelets (1 X 109/ml) were surface radiolabeled using 1251 and lactoperoxidase, washed, lysed, and used for immunoprecipitation ( 1, 5) .
Dami cell preparation. Dami cells (4) were a generous gift of Dr. Sheryl M. Greenberg 370C.) platelets were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 for 3 h at 40C. Cells were embedded in 2.3 M sucrose and frozen thin sections were cut from the cell block. Immunocytochemistry was performed as described (6, 7) using polyclonal rabbit antimultimerin (1:50) and goat anti-rabbit gold-10 (Amersham Corp., Arlington Heights, IL). A double-labeling experiment to localize multimerin and von Willebrand factor was performed using protein A, as described by Slot and Geuze (8) . Rabbit antibody against multimerin was applied (dilution 1:10) and labeled with protein A-10. Before the addition of the second antibody, free protein A (0.05 mg/ml) was applied. Subsequently, rabbit antibodies to von Willebrand factor were added at a 1:10 dilution followed by protein A-5. A second experiment was also performed using the polyclonal multimerin antibody and goat anti-rabbit gold-5 and a monoclonal antibody against von Willebrand's factor (dilution 1 :10) and goat anti-mouse gold. Controls consisted of a primary incubation with normal rabbit serum.
Immunocytochemistry was performed on normal bone marrow smears and on resting and PMA-activated Dami cells. Air-dried smears were fixed in acetone at 4°C for 15 min before blocking endogenous peroxidase activity with 0.5% hydrogen peroxide in methanol for 20 min. After further air drying, the slides were rinsed in Tris-buffered saline, pH 7.6 (TBS)' and incubated for 1 h in TBS with JS-I (monoclonal antimultimerin; 1: 100-1:1,000 dilution) or TBS alone (negative control). The slides were rinsed in TBS and incubated in biotinylated rabbit anti-mouse immunoglobulins ( 10 min) and streptavidin peroxidase conjugate (5 min; Histostain SP kit; Zymed Laboratories Inc., South San Francisco, CA). Peroxidase was demonstrated using aminoethylcarbazole in acetate buffer, pH 5.0. Nuclei were counterstained with hematoxylin.
Radioimmunoprecipitation. Immunoprecipitations of 1-ml vol of radiolabeled cell lysates or culture supernatant were performed using protein A sepharose beads (50 jl) and either monoclonal (10jIl JS-I ) or polyclonal antibodies (50 ,l) against multimerin ( 1). To reduce nonspecific binding, samples from 18-h metabolic labeling experiments were subjected to two consecutive immunoprecipitations (9), using polyclonal antimultimerin. Beads were washed five times with lysing buffer (containing 0.2% Triton X-100), eluted with 100 Il of lysing buffer containing 2% SDS, 2% Triton X-100, and 2% sodium deoxycholate, and boiled. Eluates were collected, diluted 10-fold with lysing buffer (containing 0.2% Triton X-100) and a second immunoprecipitation was performed. Immunoprecipitates were used for subunit and multimer analyses ( 1, 2 agarose gels (SeaPlaque agarose; FMC Corp., FMC BioProducts, Rockland, ME) containing 1.5% acrylamide (2) . Thrombospondin was used as a reference for multimer size (2) . Individual multimer subunit composition was assessed by two-dimensional, nonreduced/ reduced electrophoresis as described (2) .
Protease mapping. Cleveland mapping was used to compare the different multimerin subunits (10) . Multimerin immunoprecipitates were prepared, reduced, and alkylated ( 1), followed by subunit separation using SDS-PAGE. The radiolabeled proteins were isolated from dried gels and protease digestion was performed in the stacking gel using V8 protease (0.05, 0.1, 0.5, and 5.0 Ag/lane), chymotrypsin (1, 10 , and 50 ig/lane) and trypsin ( 1, 10 , and 50 ig/lane). Peptides were resolved using 7-15% SDS-PAGE.
Carbohydrate analysis. The carbohydrate content of multimerin was assessed by exo and endoglycosidase digestions (9, 11 Studies performed on frozen thin sections of thrombin-activated platelets demonstrated that the multimerin was located on the external plasma membrane and within the surface-connected cannalicular system after platelet activation ( Fig. 1 c) Figure 1 . Immunogold labeling of multimerin in frozen thin sections of resting and activated platelets. In resting platelets, labeled using polyclonal antibodies to multimerin and goat anti-rabbit gold-lO (panel a, x50,000), the gold particles were found within the alpha granule matrix, usually in an eccentric position (large arrows). Rare label was detected on the plasma membrane (pm). Double labeling studies of resting platelets (inset of an alpha granule, panel a, x98,000) were performed using polyclonal antibodies to multimerin (detection with protein A gold-1O) and to von Willebrand factor (detection with protein A gold-5; small arrows). Multimerin (the large gold) and von Willebrand factor (the small gold) colocalized to the same region of the alpha granules. In panel b (x60,000), von Willebrand factor was detected with a monoclonal antibody and goat anti-mouse gold-IO, and multimerin was detected with a polyclonal antibody and goat anti-rabbit gold-5. The results are similar to panel a, and short arrows point to the granules with eccentric double-labeling.
Thrombin-stimulated platelets (panel c, x42,000) exhibited shape change and aggregation. Immunocytochemistry using polyclonal antibodies to multimerin and goat anti-rabbit gold-10 demonstrated presence of gold in large vacuoles (v) many of which are probably sections of the surface-connected cannalicular system. Smaller amounts ofthe label were localized to the external plasma membrane. No label was detected in the tight "contact zones" (CZ). (Fig. 3) .
When the intracellular and secreted multimerin from an 18-h metabolic labeling were compared, the proteins differed in their reduced subunit size. The 1 70-kD band was the predominant protein in the cell lysate (Fig. 3) . The secreted protein was comprised of 196-and 1 65-kD subunits, with a greater proportion ofthe larger subunit (Fig. 3) unit (Fig. 4) . The observed differences may be due to a longer peptide sequence in p-1 96, differences in glycosylation between the protein synthesized in vivo and in vitro, or the distribution of the different radiolabels on the individual peptides. Carbohydrate composition of multimerin. Glycosidase digestions were performed to determine the carbohydrate composition of multimerin and to further investigate the differences in subunit sizes (Fig. 5) . The platelet p-155 and p-170 multimerin subunits contained similar quantities of N-linked carbohydrate (Fig. 5, lane 4) and sialic acid (Fig. 5, lane 2) . Removal ofall N-linked carbohydrate by N-glycosidase F from p-170 and p-155 resulted in proteins with mobilities of 120 and 105 kD, respectively (Fig. 5, lane 4) . Resistance of p-155 and p-170 to endoglycosidase F and endoglycosidase H (Fig. 5,  lanes 6 and 11) , indicated that p-155 and p-170 contain only the complex forms of N-linked carbohydrate. In contrast to the results obtained using N-glycosidase F, O-glycanase treatment resulted in only a minor shift in mobility of the p-155 subunit (Fig. 5, lane 21) (Fig. 5, lane 16) . Additionally, the secreted Dami cell multimerin was resistant to endoglycosidase F (Fig.  5, lane 12) and to endoglycosidase H (Fig. 5, lane 10 (Fig. 5, lane 16) . Because the deglycosylated p-155 platelet multimerin subunit was smaller (Fig. 5, lane 15) than the deglycosylated subunits of multimerin from Dami cells (Fig. 5, lane 16) , we postulate that there is more complete proteolytic processing of the protein derived from platelets.
The 1 96-kD Dami cell multimerin subunit contained sialic acid that was not completely removed by treatment with N-glycanase F (Fig. 5, lanes 16 and 18) , suggesting the presence of O-linked carbohydrate. O-glycanase digestion resulted in a 9-kD mobility shift in the neuraminidase-treated 1 96-kD subunit (Fig. 5, lanes 20 and 22) , confirming the presence of O-linked sugars on the p-196 subunit ofmultimerin. However, complex, N-linked carbohydrate is the predominant type.
Processing ofmultimerin during biosynthesis. Pulse-chase studies were undertaken to follow the processing ofmultimerin during its biosynthesis. Dami cells were metabolically labeled (20 min) and biosynthesis was followed in the culture supernatants and cell lysates at varying chase intervals after pulse labeling (Fig. 6 ). This study demonstrated that the first multimerin subunit synthesized was 170 kD. Subsequently the 196-kD protein became detectable in the cell lysate with the amount progressively increasing over the next hour. Secretion of the protein was first detected at 1 h and almost all of the synthe- We postulated that the increase in the molecular weight of multimerin subunit during biosynthesis was due to the addition of carbohydrate. Additionally, because the pulse-chase studies indicated rapid secretion, we postulated that the intracellular multimerin from 18-h labeling experiments was mainly the recently synthesized, precursor form ofthe protein.
To address these issues, the multimerin prepared from 18-h metabolic labeled Dami cell lysate was compared to the precursor protein synthesized during a 0.5-h metabolic labeling (Fig.   7 a) . Both lysates contained a 1 70-kD multimerin subunit that was susceptible to endoglycosidase H digestion, indicating the Multimerin Biosynthesis and Localization in Platelet a-Granules (Fig. 3) . This may represent a co- , and 20 h after pulse and analyzed by SDS-PAGE. This study demonstrates that multimerin is synthesized as a 1 70-kD subunit, followed by further processing to generate the secreted 196-and 165-kD subunits. The larger 196-kD subunit first appears in the cell lysate at 0.5 h and its appearance is rapidly followed by secretion of 196-and 165-kD subunits. Almost all of the synthesized protein was secreted by 3 h. The band at 140 kD in the cell lysate was not consistently seen in other pulse chase experiments and may represent a coprecipitated protein.
tein that migrated at 132 kD (Fig. 7 b, lane 3) in contrast to the 170-kD protein synthesized in the absence of tunicamycin (Fig. 7 b, lane 2) . The endoglycosidase H treatment of the early precursor protein resulted in an equivalent reduction in apparent M, (Fig. 7 a) , suggesting that the 1 70-kD multimerin precursor contained only high mannose forms of N-linked carbohydrate.
Further studies were performed to investigate 0-glycosylation during the biosynthesis of multimerin. The presence of O-linked carbohydrate was suggested by the higher M, of the N-deglycosylated, 196-kD secreted multimerin subunit (Fig. 7  b, lane 5) , compared with the 132-kD protein synthesized in the presence oftunicamycin (Fig. 7 b, lane 3) . The presence of O-linked carbohydrate was confirmed by demonstrating that neuraminidase reduced the Mr of the N-deglycosylated p-196 (Fig. 7 b, lane 4; Fig. 5, lane 18) and O-glycanase further reduced the M, of p-196 (Fig. 5, lane 22) . The N-deglycosylated, secreted p-165 was smaller than the precursor protein synthesized in the presence of tunicamycin (Fig. 7 b, lanes 5 and 3) , indicating that production of the smaller subunit of the secreted protein requires proteolysis. The observed differences in migration of the Dami cell p-165 and platelet p-170 multimerin subunits may reflect differences in either glycosylation or proteolysis.
Because the megakaryocytic cell line synthesized a larger multimerin subunit than found in platelets, we looked for evidence that the multimerin contained within platelets had originated from a larger precursor protein. A 200-kD band was occasionally observed in reduced multimerin immunoprecipitates from surface-labeled thrombin-activated platelets. To determine ifthis protein was a component ofmultimerin, two-dimensional nonreduced/reduced electrophoresis was performed. The 200-kD protein was present within the multimerin multimers, covalently linked to the p-155 and p-170 subunits by interchain disulfide bonds (Fig. 8) .
Comparison ofthe multimeric composition ofplatelet multimerin and the multimerin secreted by Dami cells. Agarose/ acrylamide gels were used to investigate the nonreduced struc- munoprecipitates were prepared from Dami cell culture supernatants (18-h metabolic labelings) and from surface radiolabeled, thrombin-activated platelets. In comparison to the multimers from platelets, the constitutively secreted multimers from Dami cells were comprised mainly of the smallest multimers of the protein (Fig. 9) . Two-dimensional, nonreduced/ reduced electrophoresis demonstrated that the different sized subunits of Dami cell multimerin were linked by interchain disulfide bonds.
Discussion
Multimerin is an unusually large, disulfide-linked, multimeric protein that exhibits variability in its native multimeric size, ranging from less than 450 kD to many million Daltons (2). In our previous studies, we demonstrated that it was a unique, soluble platelet protein and demonstrated the activation-dependent nature of multimerin expression on the platelet surface (1) . Further investigation demonstrated that multimerin resembles von Willebrand factor in its complex multimeric composition and that multimerin and von Willebrand factor are the two largest proteins in platelets (2) . The purpose ofthe studies described in this report was threefold. The first studies were designed to determine the intracellular location of multimerin in platelets. The second series of investigations focused on identifying ifthe protein was present in megakaryocytes and whether it could be synthesized by Dami cells, a malignant megakaryocytic cell line. The third series of studies investigated the similarities and differences between the platelet and Dami cell forms of multimerin. Previously, we have shown that multimerin is a soluble protein contained within platelets (1) . Platelet activation results in a dramatic increase in the expression of multimerin on the platelet surface ( 1). In the current studies, we used immunoelectron microscopy to demonstrate that multimerin was contained within the a granules ofresting platelets. Because the eccentric location of multimerin within the a granule resembled that of von Willebrand factor ( 12) , dual labeling experi-P D Figure 9 . (3) . In contrast, endogenously synthesized platelet proteins typically are present in greater concentration within platelets compared to plasma (3). Our previous studies failed to identify multimerin as a constituent of normal plasma ( 1 ) . As a result, we postulated that multimerin was synthesized by megakaryocytes, then stored within granules.
Confirmation of endogenous biosynthesis by megakaryocytes was obtained using Dami cells, a megakaryocytic cell line. These cells synthesize a variety ofplatelet glycoproteins including von Willebrand factor (4). Immunohistochemistry demonstrated the presence of multimerin in normal megakaryocytes and in Dami cells (Fig. 2) . Furthermore, using metabolic labeling, we demonstrated that PMA-activated Dami cells were able to synthesize multimerin (Fig. 3) (Fig. 4) . The Dami cell protein further resembled platelet multimerin in its soluble nature and disulfide-linked multimeric structure.
We have shown that platelet multimerin is primarily comprised of a 1 55-kD subunit with a smaller amount of a 1 70-kD subunit. Using protease digestion, peptide homology was demonstrated between these two proteins (Fig. 4) . Glycosidase digestion ofthe p-155 and p-170 proteins demonstrated that both proteins were heavily glycosylated, containing mainly complex, N-linked carbohydrate (Fig. 5 ) . Deglycosylation ofp-155 and p-170 yielded different sized proteins, demonstrating that p-170 contains a larger polypeptide component. Together, these observations suggest that the p-155 protein is derived from the p-170 protein by proteolytic cleavage.
Next, pulse-chase metabolic labeling studies were used to follow the biosynthesis of multimerin. Multimerin was synthesized as a 170-kD precursor containing high mannose, Nlinked carbohydrate, as evidenced by susceptibility to endoglycosidase H digestion (Figs. 6 and 7) . Subsequent modification included the processing of N-linked carbohydrate from high mannose to complex forms and the addition ofO-linked carbohydrate to generate a 196-kD subunit. Removal ofall N-linked carbohydrate from the mature, 196-kD subunit produced a 5 l-kD shift in apparent molecular mass, which would indicate approximately 17 N-glycosylation sites on the multimerin precursor protein ( 11) . Proteolysis resulted in the production of a smaller, 165-kD, secreted multimerin subunit.
In contrast to platelet multimerin, the protein synthesized and secreted by Dami cells differed in its subunit sizes. The rapid secretion of multimerin synthesized in vitro by the PMAactivated Dami cells may account for less complete proteolytic processing compared to platelet multimerin synthesized in vivo. Similar incomplete proteolysis of von Willebrand factor secreted by cultured endothelial cells has been observed ( 13 ) . Additionally, the malignant Dami cells may differ from normal megakaryocytes in their expression ofthe glycosyltransferases involved in N-glycosylation. This may account for the small differences in M, observed between the Dami cell p-165 and the platelet p-1 70 multimerin subunits.
In contrast to platelet multimerin, which ranges in size up to many million Daltons (2), the multimerin synthesized and secreted by Dami cells contained less of the high molecular mass multimers (Fig. 9) . The von Willebrand factor constitutively secreted by cultured endothelial cells also has been demonstrated to contain a predominance of the smaller multimers (13) .
Our studies suggest that the platelet multimerin subunits originate from a larger precursor protein. We have occasionally observed that reduced platelet multimerin immunoprecipitates contain small quantities of a 200-kD protein that resembles the Dami cell p-196 (2). Using two-dimensional, nonreduced/reduced electrophoresis, we demonstrated that the 200-kD protein was a component ofthe disulfide-linked multimers of platelet multimerin (Fig. 8) . Collectively, the evidence suggests that multimerin is synthesized both in vivo and in vitro as a larger precursor protein and that the mature, platelet multimerin undergoes proteolysis during biosynthesis and storage.
These studies indicate that multimerin is located within the a-granules of resting platelets and redistributes to the plasma membrane and surface-connected cannalicular system following activation. Multimerin is a heavily glycosylated protein that exists as variably sized, disulfide-linked multimers of related subunits. The synthesis of multimerin by the megakaryocytic cell line supports endogenous biosynthesis by megakaryocytes. Further confirmation of a megakaryocytic origin in vivo will require the demonstration of multimerin mRNA in normal megakaryocytes. Biosynthesis occurs through a process that involves the conversion of N-linked carbohydrate to complex forms, the addition of O-linked carbohydrate, proteolysis, and the formation of disulfide-linked multimers. The unusual repeating multimeric structure of multimerin, its localization to platelets, and its activation-induced expression on the platelet surface suggest a physiologic role in the cellular events associated with vascular injury.
